Clinical Trials Browser

Terminated × Lymphoma, B-Cell × Antilymphocyte Serum × Clear all

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2 Terminated

3 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse